TSO3 — Investor Presentation (May 2018)
18 slides from TSO3's investor presentation, May 2018
Slide 1: To Create and Deliver the New Standard of Care in Sterile Reprocessing
To Create and Deliver the New Standard of Care in Sterile Reprocessing™ Investor Presentation | May 2018 1
Slide 2: Important Cautions Regarding Forward Looking Statements and Other Disclosures
Important Cautions Regarding Forward Looking Statements and Other Disclosures The statements contained in this presentation and oral statements made by representatives of TSO3 Inc. (“Company”) relating to matters that are not historical facts are forward-looking statements that involve certain risks
Slide 3: Vision. Purpose: The New Standard of Care in Sterile Reprocessing
VISION. PURPOSE. To Create and Deliver The New Standard of Care In Sterile Reprocessing™ A Sterile Device for Every Patient 3
Slide 4: One Disruptive Technology – Two Large Markets
One Disruptive Technology – Two Large Markets Established Base Business Emerging Opportunity Operating Room & Central Sterile Process/ Gastrointestinal Supply Department Technology ~15M colonoscopies performed annually2 U.S. ~10,000 Hospitals & Ambulatory Surgery Centers1 >500,000 ERCP Procedures (e
Slide 5: Value of a Customer
Value of a Customer Revenue Potential Per Customer* (Assuming 2 units, 10 Yr Product Life) “Razor” Capital Equipment Sales $240k-$300k 1-4 units per facility Approx. Higher-Margin Assuming 4-5 Cycles/Day, 250d/yr $0.9m-$1.2m Proprietary Consumables Revenue $50k-$62.5k/yr ~$20-30/cycle (dep. on mix a
Slide 6: Disruptive Technology for OR Support
Disruptive Technology for OR Support The STERIZONE® VP4 Sterilizer is a dual sterilant, low-temperature sterilization system that uses vaporized hydrogen peroxide (H2O2) and ozone. Features Advantages Benefits • Dual Chemistry • Simple Single Cycle • Lowest Cost per Instrument Operation Sterilized •
Slide 7: Proven Value Proposition
Proven Value Proposition* New Metric: Cost per Instrument Sterilized, not Cost per Cycle Competition STERIZONE® VP4 Sterilizer Saves up to 50% in Operating Costs 2 STERIZONE® VP4 Sterilizers = 3+ of the Competition in Throughput The Least Expensive Option In the Market Today * Actual customer result
Slide 8: Commercialization Approach - CSSD
Commercialization Approach - CSSD LEVERAGE EARLY INCREASE MARKET ESTABLISH STRONG SUPPORT WITH DIRECT ADOPTERS AWARENESS CUSTOMER SALES, CLINICAL AND TARGETING METRICS TECHNICAL PERSONNEL • Over 50 sterilizers • TSO3 has targeted and • High Use Facilities installed in US, Canada connected with 531+
Slide 9: Sales and Marketing Activities
Sales and Marketing Activities • Sell Direct to End Users Direct Sales – In initial months: >531 Hospitals Contacted • Consultive Sales Approach >40 units quoted Getinge Sales Growing installation base • Sell With Partners More in the pipeline • Getinge Infection Control • Sales Agents • New Approac
Slide 10: Endoscopy Sterilization – A Greenfield Opportunity
Endoscopy Sterilization – A Greenfield Opportunity Established Base Business Emerging Opportunity Operating Room & Central Sterile Process/ Gastrointestinal Supply Department Technology ~15M colonoscopies performed annually2 U.S. ~ 10,000 Hospitals & Ambulatory Surgery Centers1 >500,000 ERCP Procedu
Slide 11: How Shifts Happen
How Shifts Happen Patient and Medical Technology Facility Demand Advancement • Patient Safety • STERIZONE® VP4 Sterilizer • Litigation • Cost Reduction Market Change Regulatory Change • FDA Regulation Advancement • Industry Dialogue and Guidelines TSX:TOS 11
Slide 12: Modernizing GI Endoscope Reprocessing
Modernizing GI Endoscope Reprocessing Decades old processes with incremental improvement “Despite reprocessing in accordance with US guidelines, viable Old microbes and biologic debris persisted in clinically used [GI] endoscopes, suggesting current reprocessing guidelines are not sufficient to ensu
Slide 13: Shift is Happening
Shift is Happening • VA Officials Get • Dirty Endoscopes • Dirty Instruments Lead to • Nightmare Bacteria And Dirty Scopes - • An Epidemic is on the Rise that May • The Effectiveness of Sterilization for Probed For Using Raising Alarms for Investigation of Seattle Hospital Ignorance And Want in Medi
Slide 14: TSO3 Obtains Expanded Endoscope Clearances
TSO3 Obtains Expanded Endoscope Clearances May 9, 2018 - TSO3 received FDA 510(k) clearance for the terminal sterilization of multi-channeled flexible endoscopes using the Company’s STERIZONE® VP4 Sterilizer • Hospitals can terminally sterilize gastrointestinal endoscopes within the cleared intended
Slide 15: GI Commercialization Approach
GI Commercialization Approach Value Proposition to Hospital • Improve Patient Safety • Manage Reputational Risk • Manage Litigation Risk • Future Proofing the CSSD Evidence Based Practice: • Leverage Existing Industry Leading Claims • Colonoscopes, Duodenoscopes and Gastroscopes • Higher Efficiency
Slide 16: Next Generation Technology, Extensive Patent Portfolio, Razor/Razorblade
Next Generation Technology Extensive Patent Portfolio Razor/Razorblade Razor/Razorblade Business Model First- First-to- to-Market FDA- FDA-cleared Device for Terminal Sterilization of Colonoscopes, Duodenoscopes and Gastroscopes Co- Co-Commercial Strategy for North America with Global Distribution P
Slide 17: Key Stats (TSX: TOS)
Key Stats (TSX: TOS) /// All Dollars in USD, Unless Noted Otherwise Stock Price (5/23/18) CAD$0.95 52 Week High-Low CAD$3.30-$0.56 Shares Outstanding (mrq) (no warrants) 92.9M Average Daily Volume (90 day) 230,100 Market Capitalization CAD$88.3M Institutional Holdings ~31% Total Revenue (mrq) $0.3M
Slide 18: T Sh,
T Sh,